Table 3.
Summary of the cell sources for vascular tissue engineering, their advantages, and limitations.
| Cell type | Source | Differentiation to vascular cells | Advantages | Limitations | Examples |
|---|---|---|---|---|---|
| Somatic cells | Somatic tissues | Fully differentiated at the time of isolation | • Standardized isolation methods • Reflect the phenotype of native vascular cells |
• Invasive isolation methods • Limited replication capacity |
(33) |
| Induced pluripotent stem cells | Skin- derived, EPCs-derived | Differentiate into vascular endothelium and smooth muscle cells (58) | Robust source of autologous cells | • Low reprogramming efficiency • Need to establish more robust differentiation protocols. • Genetic and epigenetic alterations |
(19, 22, 32, 59, 60) |
| Mesenchymal stem cells | Bone marrow, Cord and peripheral Blood | Differentiate into vascular endothelial and smooth muscle cells (61) | • Could be isolated from a wide range of tissues • Antithrombotic properties |
• Difficult isolation and identification • Heterogeneity of MSC population • Lower regenerative potential in some pathologies such as diabetes |
(8, 20, 31) |
| Adipose derived stem cells | Adipose tissue (stromal vascular fraction) | Differentiate to smooth muscle and endothelial cells | Similar to MSCs in terms of morphology, phenotype and differentiation potential | • Differentiation to fully mature endothelial phenotype is limited • Altered cytoskeletal integrity in ASCs engineered tissues (62) |
(63) |
| Endothelial progenitor cells | Cord and peripheral Blood, bone marrow | Differentiate to mature endothelial cells, with potential of endothelial-mesenchymal transition | • Accessible cell source • Stable mature endothelial phenotype (late EPCs) • Robust proliferation |
• Relatively prolonged and expensive isolation methods • Heterogeneity and uncertainty of the resulting phenotypes from different origins/isolation methods • Cells emergence could be lower in certain pathologies (e.g., Diabetes and cardiovascular disease) |
(64–67) |
| Embryonic stem cells | Early-stage embryos (inner cell mass of a blastocyst) | Differentiate to smooth muscle and endothelial cells | Could be maintained for long durations in culture | • Ethical, political and religious controversies • Sourcing difficulties • Low efficiency to generate stable endothelial cell phenotype. |
(68) |